학술논문

Preoperative De Ritis Ratio for the Evaluation of Recurrence and Progression in Non-muscle Invasive Bladder Cancer.
Document Type
Article
Source
Üroonkoloji Bülteni. Mar2023, Vol. 22 Issue 1, p15-19. 5p.
Subject
*DISEASE progression
*C-reactive protein
*ALBUMINS
*PREDICTIVE tests
*ACADEMIC medical centers
*PREOPERATIVE period
*CANCER relapse
*TRANSURETHRAL resection of bladder
*RETROSPECTIVE studies
*NON-muscle invasive bladder cancer
*NEUTROPHIL lymphocyte ratio
*DESCRIPTIVE statistics
*TUMOR markers
*BLOOD testing
*RECEIVER operating characteristic curves
Language
ISSN
2147-2270
Abstract
Objective: This study aimed to investigate the potential predictive value of the preoperative De Ritis ratio in patients with primary non-muscle invasive bladder cancer (NMIBC). Materials and Methods: Of 212 patients who underwent transurethral resection of bladder tumour surgery for primary bladder cancer at a single academic centre between 2010 and 2016, we retrospectively analysed the clinical and pathological data. Blood samples were collected 1-7 days before surgery. The De Ritis ratio's potential prognostic value of was evaluated using receiver operating characteristic (ROC) curve analysis. Results: One hundred twenty-five patients (or 59%) were found to have high-risk diseases, 17 patients (or 8%) had intermediate-risk diseases, and 70 patients (or 33%) had low-risk diseases. We investigated which cut-off value for De Ritis ratio could predict NMIBC risk groups in the preoperative period. The ROC analysis showed that there was no significant cut-off value in either low-risk [area under the curve (AUC)=0.457] or high-risk (AUC=0.551) patients. According to the European Organization for Research and Treatment of Cancer risk groups, when the quantitative values were compared, it was seen that low-risk patients were younger (p=0.005) and this group's alanine aminotransaminase (p<0.001) values were higher. De Ritis ratio was statistically similar in all patient groups. Conclusion: According to our present results, the De Ritis ratio does not add any additional value to existing prognostic models. Investigating De Ritis ratio simultaneously with markers such as albumin, C-reactive protein, neutrophil-lymphocyte ratio, which are used successfully in many cancer types, may yield successful results in prospective, more comprehensive studies. [ABSTRACT FROM AUTHOR]